Oncolytics Biotech Posts 29% and 33% Response Rates, Plans Sub-100-Patient FDA Registrational Study
Oncolytics’ GOBLET Cohort 4 anal cancer study showed 29% response with 17-month median duration, and its Fast Track colorectal cancer trial achieved 33% response with 27-month median survival. Oncolytics will meet FDA in mid-April to finalize a sub-100-patient registrational study for second-line indications, with interim data expected by year-end 2026.
1. Clinical Efficacy in Anal and Colorectal Cancer
Oncolytics Biotech’s GOBLET Cohort 4 in squamous cell anal cancer reported a 29% response rate with a 17-month median duration of response. In its Fast Track-designated trial for second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, pelareorep combined with standard chemotherapy and Avastin achieved a 33% response rate and 27-month median overall survival versus 11.2 months.
2. Regulatory Strategy and FDA Meeting
Building on Fast Track designation for pelareorep, Oncolytics will meet with the FDA in mid-April to align on a registrational study design. The protocol is expected to enroll under 100 patients in rare second-line indications, streamlining the path to potential approval.
3. Financial and Operational Positioning
The company retains sufficient cash reserves to execute its near-term registrational programs without immediate dilution, reallocating resources from exploratory GOBLET cohorts to high-conviction registration studies. This financial flexibility supports an efficient development timeline.
4. Timeline and Future Milestones
Oncolytics plans to activate the first clinical site of its controlled registrational study in March 2026 and expects to report interim data by year-end 2026. Positive interim results could catalyze a full FDA submission in these second-line cancer settings.